Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a major
cause of cancer-related morbidity and mortality around the world. Frequently, concurrent
liver dysfunction and variations in tumor burden make it difficult to design effective
and standardized treatment pathways. Contemporary treatment guidelines designed for
an era of personalized medicine should consider these features in a more clinically
meaningful way to improve outcomes for patients across the HCC spectrum. Given the
heterogeneity of HCC, we propose a detailed clinical algorithm for selecting optimal
treatment using an evidence-based and practical approach, incorporating liver function,
tumor burden, the extent of disease, and ultimate treatment intent, with the goal
of individualizing clinical decision making.
Keywords
radioembolization - yttrium-90 - downstaging - transplantation - survival - interventional
radiology
